EvoNK Ovarian Cancer Immunotherapy
Why is ovarian cancer maintenance important?
Limitations of existing treatments and differences between LACELLIC
Why EvoNK is different
EvoNK immune cell therapy
The key to ovarian cancer maintenance suggested by LACELLIC
LACELLIC Ovarian Cancer Medical Tour
LACELLIC Medical Tour Package Ovarian cancer is known as a gynecological cancer whose early symptoms are not clear, so detection may be delayed.
In many cases, it feels similar to symptoms commonly experienced in everyday life, such as abdominal bloating, indigestion, or discomfort in the pelvic area, so it is easy to overlook.
A frequently mentioned aspect of the course after treatment is recurrence. It has been reported that even after surgery and chemotherapy, there may remain microscopic residual cancer that cannot be identified on imaging tests, and this may lead to recurrence over time.
Therefore, ovarian cancer is said to be a disease in which how to proceed after treatment is discussed rather than when treatment ends.
However, an individual's condition cannot be judged based on these descriptions alone. Confirmation through imaging tests, tumor marker tests (CA-125, etc.), and gynecological oncology specialist treatment should be prioritized. Methods that have been considered together so far
Surgical treatment and chemotherapy are standard treatments for ovarian cancer, after which regular follow-up and maintenance therapy are planned according to the condition.
These treatments play an important role in shrinking the tumor and managing recurrence and are at the discretion of your medical team.
On the one hand, it has been mentioned that while treatment continues, a burden is accumulated on the entire body's physical strength, and that it is not easy to reach cancer stem cells (CSCs) that remain deep in the tumor microenvironment (TME) and show resistance to treatment.
At this point, research is continuing on approaches that look at the body's immune function itself. Our body’s immune cells — LACELLIC’s EvoNK
NK cells (natural killer cells) are immune cells that originally exist in our body and are known to play a role in recognizing and eliminating abnormal cells.
LACELLIC's EvoNK is an immune cell platform that goes beyond simply collecting and cultivating these NK cells and engineered them to survive for a long time in the body and function accurately.
As a result of experiments conducted by LACELLIC Cell Regenerative Medicine Research Institute, it was confirmed that anti-tumor activity is up to 5 to 20 times higher than that of existing NK cells. Here's where EvoNK comes together in ovarian cancer maintenance:
• Targeted removal of cancer stem cells (CSCs), which are believed to be the cause of recurrence • Tracking of microscopic residual cancer (MRD) that cannot be captured on images • Dual NK activation by looking at both the inside and outside of the tumor microenvironment (TME) • Aiming at rebuilding systemic immunity that has decreased after anti-cancer treatment
It is designed with a dual structure that administers externally manufactured highly active NK cells and simultaneously activates the original NK cells within the body.
Rather than pushing the treatment too hard, the program is designed to maintain the immune defense environment for a long time while maintaining daily life after completing treatment.
However, for ovarian cancer, the application and method vary depending on the stage and tissue type, the extent of surgery and anticancer treatment already received, the maintenance treatment currently in progress, and the overall condition.
Since the composition of a program and its applicability to a specific individual are two different issues, priority is given to the individual review process after sufficient testing and consultation with medical staff.
Also, please understand that this is not a concept of eliminating recurrence, but rather an approach aimed at lowering the risk of recurrence and maintaining an immune defense environment for a long time.
The priority is to continue the standard treatment and regular follow-up currently in progress at the discretion of the medical staff in charge, and the cell program is not a replacement for this. Do not stop treatment arbitrarily and be sure to consult your doctor.
Medical tour information for overseas patients
For overseas patients, not only medical treatment and treatment, but also the schedule before and after visiting Korea must be considered.
At LACELLIC, overseas patients can schedule domestic treatment.
To help you prepare more conveniently, we provide consultation regarding treatment schedules and medical tourism.
Information on movement and stay after arrival at the airport, remote tracking of immunity levels and follow-up care after returning home, and connection with global partner networks in Southeast Asia, the Middle East, and the Americas are also provided.
The basic schedule is a one-time visit to Korea, from precise diagnosis to cell transplantation, and then repeated visit cycles and ongoing management based on the EvoX platform are reviewed. The specific scope of support may vary depending on the patient's schedule and program and can be confirmed through prior consultation.
The method of application of cell programs may vary depending on the individual's condition. LACELLIC also prioritizes the process of confirming applicability based on sufficient testing and consultation with medical staff.
The 5 to 20 times in the text are the results of experiments at LACELLIC Cell Regenerative Medicine Research Institute and do not guarantee individual treatment results.
The scope of support for global partner network connections may vary depending on the partner organization and country, and may not be available in all regions. Progress and results may vary depending on the individual's condition.
LACELLIC Clinic 6th and 7th floors, 503 Bongeunsa-ro, Gangnam-gu, Seoul 71-9 Samseong-dong, Gangnam-gu, Seoul
Inquiry +82 10-7667-6057
LACELLIC Clinic 6th and 7th floors, 503 Bongeunsa-ro, Gangnam-gu, Seoul
